Indero Announces Breakthrough Method for Early Phase Testing of Top Drugs Using Gene Expression

Content of the article

Montreal – Indero is proud to announce the successful completion of an internally funded research project that presents a novel method for testing new topical chemicals (NCE) in early phase clinical research. This new method makes multi-gene analysis of drug efficacy fast and cost-effective.

Content of the article

Dr Robert BissonNnette, executive chairman and co-founder of Indero, who initiated and led the study, shared his excitement about the results:

Content of the article

“Our goal was to rethink how to study top drugs in early phase studies. The results of this study show

Content of the article

which calls for microdosing for only three days

Content of the article

it can provide signals of meaningful success. Within 24 hours, we observed changes in gene expression after applying a medium-sized microdose of corticosteroid to the patients’ skin. At 72 hours, TH2, TH22 and th17-th17-specific cells were reduced. This result is exactly what we set out to do and it opens the door to faster, smarter drug development techniques, demonstrating the power of this approach that has been successfully used in early studies 1.”

Content of the article

The course highlights several advantages of this approach:

Content of the article

Quick and easy understanding with limited requirements for detoxification and reduced costs 1 cost (three-day study (3-day study).
The ability to compare multiple nces, concentrations, and movements within the same patient in short-term studies.
An opportunity to take a closer look at the capabilities of combating well-approved topical drugs.

Content of the article

Emma Guttman, Professor and Chair of Dermatology at Mount Sinai, analyzed the definitions of the species, emphasizing their impact:

Content of the article

“This strategy represents a paradigm shift in the development of advanced drugs. It allows doctors and investigators to accelerate patients and the program of dermatology and the Department of Dermatology and the Department of Conditions, and the director, laboratory Inflammatory skin diseases, ICAHN school of medicine at Mount Sinai.

Content of the article

This breakthrough puts indero at the forefront of dermatology research, creating a faster, safer, and more cost-effective way to develop advanced treatments.

Content of the article

About Indeo

Content of the article

Indero is a CRO specializing in Dermatology and Rheumatology, with over 25 years of experience in clinical research and case delivery. Our fully functional approach that includes everything from patient design and patient recruitment provides biotech and pharmaceutical sponsors with a critical scientific base and solid technology their studies need to reach the finish line efficiently and effectively. With capabilities in North America, Europe, Latin America, and Asia-Pacific; Extensive, ongoing relationships with investigators and patients; and a dedicated research clinic where we design and deliver our studies, Indero is the ideal partner for clinical needs on a global scale.

Content of the article